[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

Roche's group sales increased by 7% at constant exchange rates in the first nine months of 2025. The Pharmaceuticals Division experienced a 9% sales increase, driven by drugs like Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus. Diagnostics Division sales grew by 1%, despite pricing reforms in China. Several key drugs received regulatory approvals or positive recommendations in the US and EU, including Tecentriq, Gazyva/Gazyvaro, and Lunsumio. Positive data emerged from phase III studies on giredestrant, vamikibart and other trials. Roche is acquiring 89bio to expand its portfolio in liver disease treatments with the FGF21 analogue. New diagnostic tests for Alzheimer's disease and kidney function received EU CE marks and US approval. The company's next-generation sequencing technology achieved a record for decoding the human genome quickly. Roche raised its earnings outlook for 2025, projecting mid-single-digit sales growth. The company anticipates phase III clinical results for up to 19 new medicines by the end of the decade.